🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Contributor sign in
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆ Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity ◆ Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing ◆ Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich ◆ Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery ◆ Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma ◆ Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide ◆
Clinical Trials in Italy / NCT01763125
Recruiting Observational

Establishment of a Tumor Bank for Blood Samples

NCT01763125 · tracked via the Priya Life Science Italy tracker
Sponsor
Medical University of Vienna
Phase
Observational
Started
2003-11
Last updated
2023-03-23

Condition(s) studied

Ovarian NeoplasmsBreast NeoplasmsColorectal NeoplasmsNeoplasms of the Female GenitaliaLung NeoplasmsEndocrine Gland Neoplasms

Investigational drug(s) / intervention(s)

Blood collection

Blood collection: Blood sample is collected during routine blood collection by a medical doctor. No more than 60ml (max.) at one timepoint.

Study summary

Establishment of a tumor bank, consisting of blood samples of tumor patients and healthy people as controls. The blood samples will be collected systematically together with the corresponding clinical data. The biological samples, the clinical date together with prospective experimental date constitute the entity of the tumor bank.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
Accepted
Inclusion Criteria: * Male/Female * Age 18 to 90 years max. * Just one current known malignant disease or * Just one current inflammatory disease Exclusion Criteria: * Inflammatory disease and malignant disease * multiple malignancies * multiple diseases * underage

Primary outcome measure(s)

Trial sites (6)

FacilityCityRegionStatus
Innsbruck Medical University Innsbruck Austria Completed
University Hospitals Leuven - Department of Obstetrics and Gynaecology Leuven Belgium Completed
Charité University - Campus Virchow Chlinic Berlin Germany Recruiting
University Medical Center Freiburg Freiburg im Breisgau Germany Completed
University Clinic of Ruhr University Bochum Herne Germany Completed
European Institute of Oncology, Division of Gynecologic Oncology, Unit of Preventive Gynecology Milan Italy Withdrawn

More Medical University of Vienna trials in Italy

A Multicenter Study on Atrioventricular Regurgitation in Transthyretin Amyloid Cardiomyopathy: Definition, Prevalence, and Prognostic Impact. Recruiting
A Prospective Randomized Trial of ECP in Subclinical AMR Recruiting

Other trials for the same condition

A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer Active, not recruiting
A Long-term Treatment Extension Study of Niraparib in Participants Who Completed a Prior GlaxoSmithKline/TESARO-sponsored Niraparib Study Recruiting
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors Recruiting
A Study of Niraparib (GSK3985771) Maintenance Treatment in Participants With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy Active, not recruiting
PREgnancy and FERtility Registry Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT01763125 on ClinicalTrials.gov ↗ ← All trials in Italy